title: Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
abstract: BACKGROUND
  Older age has been associated to serious adverse events (AE) following yellow fever (YF) vaccination in passive surveillance studies, but few prospective studies involving seniors have been published.
  
  
  RESULTS
  A total of 906 persons were evaluated; 78 were not vaccinated and 828 received the vaccine; 700 (84.7%) were interviewed after vaccination: 593 (84.7%) did not report any symptoms or signs following YF vaccine; 107 (15.3%) reported at least one AE temporally associated to YF vaccination: 97 (13.9%) had systemic AE and 17 (2.4%) reported AE at the injection site (7 had both systemic and local AE). Data regarding previous vaccination was available for 655 subjects. Statistically significant higher rates of systemic AE were observed among subjects who received the first YF vaccination (17.5%) in comparison to persons who had been previously vaccinated (9.5%).
  
  
  METHODS
  This observational prospective study aimed to describe AE following YF vaccination in persons aged ≥ 60 y. From March 2009 to April 2010, seniors who sought YF vaccination at a reference Immunization Center in São Paulo city, Brazil, were included. Demographic and clinical data, previous YF vaccination, travel destination and the final decision regarding YF vaccination or not were collected from standardized medical records. Active AE assessment was done through telephone or electronic mail interview performed approximately 14 d after immunization.
  
  
  CONCLUSIONS
  Most persons aged ≥ 60 y may be safely vaccinated against YF. Before vaccination, they must be carefully screened for conditions associated to altered immunocompetence and for risk of exposure to YF.
authors.affiliation: Centro de Referência para Imunobiológicos Especiais (CRIE); São Paulo, Brazil; Clínica de Moléstias Infecciosas e Parasítárias do Hospital das Clínicas da; São Paulo, Brazil.
authors.forename: Karina Takesaki
authors.initials: KT
authors.lastname: Miyaji
authors.forename: André Machado
authors.initials: AM
authors.lastname: Luiz
authors.forename: Amanda Nazareth
authors.initials: AN
authors.lastname: Lara
authors.forename: Tania
authors.initials: T
authors.lastname: do Socorro Souza Chaves
authors.forename: Roberta de Oliveira
authors.initials: Rde O
authors.lastname: Piorelli
authors.forename: Marta Heloisa
authors.initials: MH
authors.lastname: Lopes
authors.forename: Ana Marli Christovam
authors.initials: AM
authors.lastname: Sartori
mesh_terms: D000368:Aged; D001938:Brazil; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology* / Q000473:pathology*; D005260:Female; D006801:Humans; D015994:Incidence; D007407:Interviews as Topic; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014611:Vaccination / Q000009:adverse effects* / Q000379:methods*; D015004:Yellow Fever / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D022341:Yellow Fever Vaccine
keywords: adverse events following immunization; seniors; yellow fever vaccine